Weight Watchers Q4 Revenue of $163M, Clinical Subscribers Up 42%
Weight Watchers’ Q4 revenue reached $163 million with adjusted EBITDA of $18 million, exceeding guidance despite a $6 million net loss. Clinical subscription revenue rose 32% to $27 million as clinical subscribers climbed 42% to 130,000, and 2026 guidance targets $620–635 million revenue with $105–115 million adjusted EBITDA.
1. Fourth Quarter and Full Year 2025 Results
Weight Watchers reported Q4 total revenue of $163 million and adjusted EBITDA of $18 million, surpassing its guidance range, while recording a net loss of $6 million (3.6% margin). Full-year revenue and adjusted EBITDA also exceeded prior guidance with total end-of-period subscribers at 2.8 million.
2. GLP-1 Integration and Clinical Growth
The company’s clinical subscription revenue grew 32% to $27 million, representing 17% of total subscription revenue, and clinical subscribers increased 42% year-over-year to 130,000. Weight Watchers is combining GLP-1 medication access with its behavioral support platform, noting members in its GLP-1 Success Program lose 29% more body weight on average.
3. 2026 Financial Guidance and Strategic Outlook
For Q1 2026 the company expects about 2.65 million total subscribers, including 200,000 clinical subscribers, driven by concentrated marketing spend. Full-year 2026 guidance projects $620–635 million in revenue and $105–115 million in adjusted EBITDA as Weight Watchers shifts toward higher-ARPU integrated care models and recalibrates marketing investment.